- Home
- NMT vs MDXH Comparison
NMT vs MDXH Comparison
Compare NMT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- MDXH
- Stock Information
- Founded
- NMT 1993
- MDXH 2003
- Country
- NMT United States
- MDXH Belgium
- Employees
- NMT N/A
- MDXH N/A
- Industry
- NMT Finance/Investors Services
- MDXH
- Sector
- NMT Finance
- MDXH
- Exchange
- NMT Nasdaq
- MDXH Nasdaq
- Market Cap
- NMT 108.5M
- MDXH 93.1M
- IPO Year
- NMT N/A
- MDXH 2021
- Fundamental
- Price
- NMT $11.40
- MDXH $1.96
- Analyst Decision
- NMT
- MDXH Strong Buy
- Analyst Count
- NMT 0
- MDXH 2
- Target Price
- NMT N/A
- MDXH $7.00
- AVG Volume (30 Days)
- NMT 19.1K
- MDXH 145.0K
- Earning Date
- NMT 01-01-0001
- MDXH 02-26-2025
- Dividend Yield
- NMT 3.21%
- MDXH N/A
- EPS Growth
- NMT N/A
- MDXH N/A
- EPS
- NMT N/A
- MDXH N/A
- Revenue
- NMT N/A
- MDXH $84,708,000.00
- Revenue This Year
- NMT N/A
- MDXH $27.57
- Revenue Next Year
- NMT N/A
- MDXH $20.09
- P/E Ratio
- NMT N/A
- MDXH N/A
- Revenue Growth
- NMT N/A
- MDXH 33.01
- 52 Week Low
- NMT $9.05
- MDXH $1.55
- 52 Week High
- NMT $10.93
- MDXH $4.44
- Technical
- Relative Strength Index (RSI)
- NMT 40.70
- MDXH 38.10
- Support Level
- NMT $11.31
- MDXH $1.97
- Resistance Level
- NMT $11.60
- MDXH $2.25
- Average True Range (ATR)
- NMT 0.15
- MDXH 0.16
- MACD
- NMT -0.00
- MDXH -0.04
- Stochastic Oscillator
- NMT 57.45
- MDXH 0.00
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.